Protein kinase CK2α catalytic subunit ameliorates diabetic renal inflammatory fibrosis via NF-κB signaling pathway

Biochemical Pharmacology

Volumn 132, Issue , 2017, Pages 102-117

  Huang, Junying ^a   Chen, Zhiquan ^a   Li, Jie ^a   Chen, Qiuhong ^a   Li, Jingyan ^a   Gong, Wenyan ^a   Huang, Jiani ^a   Liu, Peiqing ^a,b   Huang, Heqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b National and Local United Engineering Lab of Druggability and New Drugs Evaluation   (China)

Author keywords

Casein kinase 2 subunit; Diabetic nephropathy; NF B pathway; Renal fibrosis; TBB treatment

Indexed keywords

CASEIN KINASE II; GLUCOSE; I KAPPA B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN KINASE CK2 ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CASEIN KINASE 2, ALPHA, HUMAN;

ADENOVIRUS INFECTION; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTI FIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA BINDING; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; IC50; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; LUCIFERASE ASSAY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DIABETIC NEPHROPATHIES; FIBROSIS; GENETICS; INFLAMMATION; METABOLISM; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CASEIN KINASE II; CATALYTIC DOMAIN; CELLS, CULTURED; DIABETIC NEPHROPATHIES; FIBROSIS; GENE KNOCKDOWN TECHNIQUES; INFLAMMATION; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 85014587967     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.02.016     Document Type: Article

References (45)

1. [1] Roscioni, S.S., Heerspink, H.J., de Zeeuw, D., The effect of RAAS blockade on the progression of diabetic nephropathy. Nat. Rev. Nephrol. 10 (2014), 77–87.
2. [2] Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329 (1993), 1456–1462.
3. [3] Abboud, H.E., Mesangial cell biology. Exp. Cell Res. 318 (2012), 979–985.
4. [4] Schlondorff, D., Banas, B., The mesangial cell revisited: no cell is an island. J. Am. Soc. Nephrol. 20 (2009), 1179–1187.
5. [5] Cove-Smith, A., Hendry, B.M., The regulation of mesangial cell proliferation. Nephron Exp. Nephrol. 108 (2008), e74–e79.
6. [6] Ichinose, K., Kawasaki, E., Eguchi, K., Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am. J. Nephrol. 27 (2007), 554–564.
7. [7] Tuttle, K.R., Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J. Am. Soc. Nephrol. 16 (2005), 1537–1538.
8. [8] Navarro-Gonzalez, J.F., Mora-Fernandez, C., Muros, D.F.M., Garcia-Perez, J., Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7 (2011), 327–340.
9. [9] Navarro, J.F., Mora, C., Role of inflammation in diabetic complications. Nephrol. Dial. Transplant. 20 (2005), 2601–2604.
10. [10] Navarro-Gonzalez, J.F., Mora-Fernandez, C., The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19 (2008), 433–442.
11. [11] Nam, J.S., Cho, M.H., Lee, G.T., Park, J.S., Ahn, C.W., Cha, B.S., et al. The activation of NF-kappaB and AP-1 in peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. Diabetes Res. Clin. Pract. 81 (2008), 25–32.
12. [12] Nagarajan, R.P., Chen, F., Li, W., Vig, E., Harrington, M.A., Nakshatri, H., et al. Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB. Biochem. J. 348:Pt. 3 (2000), 591–596.
13. [13] Chen, S., Khan, Z.A., Cukiernik, M., Chakrabarti, S., Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am. J. Physiol. Endocrinol. Metab. 284 (2003), E1089–E1097.
14. [14] Park, C.W., Kim, J.H., Lee, J.H., Kim, Y.S., Ahn, H.J., Shin, Y.S., et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 43 (2000), 1544–1553.
15. [15] Wang, S., Yang, Z., Xiong, F., Chen, C., Chao, X., Huang, J., et al. Betulinic acid ameliorates experimental diabetic-induced renal inflammation and fibrosis via inhibiting the activation of NF-kappaB signaling pathway. Mol. Cell. Endocrinol. 434 (2016), 135–143.
16. [16] Patwardhan, R.S., Sharma, D., Thoh, M., Checker, R., Sandur, S.K., Baicalein exhibits anti-inflammatory effects via inhibition of NF-kappaB transactivation. Biochem. Pharmacol. 108 (2016), 75–89.
17. [17] Graczyk, D., Debski, J., Muszynska, G., Bretner, M., Lefebvre, O., Boguta, M., Casein kinase II-mediated phosphorylation of general repressor Maf1 triggers RNA polymerase III activation. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 4926–4931.
18. [18] Zhang, Q., Soderland, D., Steinle, J.J., TNFalpha inhibits IGFBP-3 through activation of p38alpha and casein kinase 2 in human retinal endothelial cells. PLoS One, 9, 2014, e103578.
19. [19] Eom, G.H., Cho, Y.K., Ko, J.H., Shin, S., Choe, N., Kim, Y., et al. Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation 123 (2011), 2392–2403.
20. [20] Zhang, X., Yang, X., Yang, C., Li, P., Yuan, W., Deng, X., et al. Targeting protein kinase CK2 suppresses bladder cancer cell survival via the glucose metabolic pathway. Oncotarget, 2016.
21. [21] Montenarh, M., Protein kinase CK2 and angiogenesis. Adv. Clin. Exp. Med. 23 (2014), 153–158.
22. [22] Shi, J., Liu, N., Xiao, Y., Takei, Y., Yasue, M., Suzuki, Y., et al. The effects of a selective CK2 inhibitor on anti-glomerular basement membrane glomerulonephritis in rats. Biol. Pharm. Bull. 38 (2015), 1345–1351.
23. [23] Lou, D.Y., Dominguez, I., Toselli, P., Landesman-Bollag, E., O'Brien, C., Seldin, D.C., The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol. Cell. Biol. 28 (2008), 131–139.
24. [24] Rossi, M., Ruiz, D.A.I., Barella, L.F., Sakamoto, W., Zhu, L., Cui, Y., et al. CK2 acts as a potent negative regulator of receptor-mediated insulin release in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E6818–E6824.
25. [25] Meng, R., Gotz, C., Montenarh, M., The role of protein kinase CK2 in the regulation of the insulin production of pancreatic islets. Biochem. Biophys. Res. Commun. 401 (2010), 203–206.
26. [26] Welker, S., Gotz, C., Servas, C., Laschke, M.W., Menger, M.D., Montenarh, M., Glucose regulates protein kinase CK2 in pancreatic beta-cells and its interaction with PDX-1. Int. J. Biochem. Cell Biol. 45 (2013), 2786–2795.
27. [27] Al, Q.F., Montenarh, M., CK2 and the regulation of the carbohydrate metabolism. Metabolism 61 (2012), 1512–1517.
28. [28] Jung, D.H., Park, H.J., Byun, H.E., Park, Y.M., Kim, T.W., Kim, B.O., et al. Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-kappaB and AP-1 activation. Int. Immunopharmacol. 10 (2010), 1047–1054.
29. [29] Singh, N.N., Ramji, D.P., Protein kinase CK2, an important regulator of the inflammatory response?. J. Mol. Med. (Berl.) 86 (2008), 887–897.
30. [30] Geoffroy, K., Wiernsperger, N., Lagarde, M., El, B.S., Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem. 279 (2004), 34343–34352.
31. [31] Jiang, Q., Liu, P., Wu, X., Liu, W., Shen, X., Lan, T., et al. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol. Cell. Endocrinol. 331 (2011), 34–40.
32. [32] Gong, W., Chen, C., Xiong, F., Yang, Z., Wang, Y., Huang, J., et al. CKIP-1 ameliorates high glucose-induced expression of fibronectin and intercellular cell adhesion molecule-1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Biochem. Pharmacol. 116 (2016), 140–152.
33. [33] Donella-Deana, A., Cesaro, L., Sarno, S., Ruzzene, M., Brunati, A.M., Marin, O., et al. Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochem. J. 372 (2003), 841–849.
34. [34] Yamada, M., Katsuma, S., Adachi, T., Hirasawa, A., Shiojima, S., Kadowaki, T., et al. Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 7736–7741.
35. [35] Parhar, K., Morse, J., Salh, B., The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. Int. J. Colorectal Dis. 22 (2007), 601–609.
36. [36] Son, Y.K., Lee, S.M., An, W.S., Kim, K.H., Rha, S.H., Rho, J.H., et al. The role of protein kinase CK2 in cyclosporine-induced nephropathy in rats. Transplant. Proc. 45 (2013), 756–762.
37. [37] Xie, X., Peng, J., Chang, X., Huang, K., Huang, J., Wang, S., et al. Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol. Cell. Endocrinol. 369 (2013), 86–97.
38. [38] Lan, T., Liu, W., Xie, X., Xu, S., Huang, K., Peng, J., et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol. Endocrinol. 25 (2011), 2094–2105.
39. [39] Huang, K., Liu, W., Lan, T., Xie, X., Peng, J., Huang, J., et al. Berberine reduces fibronectin expression by suppressing the S1P–S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS One, 7, 2012, e43874.
40. [40] Nandipati, K.C., Subramanian, S., Agrawal, D.K., Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Mol. Cell. Biochem., 2016.
41. [41] Xie, X., Peng, J., Huang, K., Huang, J., Shen, X., Liu, P., et al. Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-kappaB signaling pathway in rat glomerular mesangial cells. Mol. Cell. Endocrinol. 362 (2012), 183–193.
42. [42] Viatour, P., Merville, M.P., Bours, V., Chariot, A., Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30 (2005), 43–52.
43. [43] Vermeulen, L., De Wilde, G., Notebaert, S., Vanden, B.W., Haegeman, G., Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem. Pharmacol. 64 (2002), 963–970.
44. [44] Wang, D., Westerheide, S.D., Hanson, J.L., Baldwin, A.J., Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J. Biol. Chem. 275 (2000), 32592–32597.
45. [45] Yu, M., Yeh, J., Van Waes, C., Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res. 66 (2006), 6722–6731.